Brucellosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1304A23.3A23.8A23.9
Who is this for?
Show terms as
34Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Brucellosis, also known as undulant fever, Malta fever, or Mediterranean fever, is a zoonotic infectious disease caused by bacteria of the genus Brucella. The most common species affecting humans include Brucella melitensis (from goats and sheep), Brucella abortus (from cattle), Brucella suis (from pigs), and Brucella canis (from dogs). Humans typically acquire the infection through consumption of unpasteurized dairy products, direct contact with infected animals or their secretions, or inhalation of contaminated aerosols. The disease is considered rare in developed countries but remains endemic in parts of the Mediterranean, Middle East, Central Asia, and Latin America. Brucellosis is a systemic infection that can affect virtually any organ system. The bacteria invade the reticuloendothelial system, affecting the liver, spleen, bone marrow, and lymph nodes. Key clinical features include undulating (wave-like) fever, profuse sweating (often with a characteristic odor), fatigue, malaise, joint and muscle pain, headache, and weight loss. Hepatosplenomegaly (enlargement of the liver and spleen) is common. Complications can involve the musculoskeletal system (sacroiliitis, spondylitis, arthritis), cardiovascular system (endocarditis, which is the leading cause of brucellosis-related mortality), central nervous system (neurobrucellosis with meningitis or encephalitis), and genitourinary system (epididymo-orchitis). The disease can follow an acute, subacute, or chronic course, and relapse is common if inadequately treated. Treatment of brucellosis requires prolonged combination antibiotic therapy. The World Health Organization recommends doxycycline combined with streptomycin or rifampicin for a minimum of six weeks. For complicated cases such as neurobrucellosis or endocarditis, treatment duration is extended and may include additional agents such as trimethoprim-sulfamethoxazole or ceftriaxone. Early diagnosis and appropriate treatment generally lead to a good prognosis, though chronic forms and relapses can occur. There is no widely available human vaccine, and prevention relies on animal vaccination programs, pasteurization of dairy products, and occupational safety measures for those working with livestock.

Clinical phenotype terms— hover any for plain English:

Septic arthritisHP:0003095Increased circulating IgG concentrationHP:0003237Abnormal hepatobiliary system physiologyHP:0025155
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Mar 2025Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases

University Hospital, Montpellier — NA

TrialNOT YET RECRUITING
Jun 2024Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy

Assistance Publique - Hôpitaux de Paris — PHASE3

TrialRECRUITING
May 2020Real World Study of Classic Infectious Disease

Huashan Hospital

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Brucellosis.

View clinical trials →

No actively recruiting trials found for Brucellosis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Brucellosis community →

Specialists

Showing 25 of 34View all specialists →
AA
Akhtar Atiya
Specialist
1 Brucellosis publication
FM
Falk Melzer
Specialist
2 Brucellosis publications
HN
Heinrich Neubauer
Specialist
2 Brucellosis publications
KQ
Kamal A Qureshi
Specialist
1 Brucellosis publication
AP
Adil Parvez
Specialist
1 Brucellosis publication
SK
Shweta Kumar
AUSTIN, TX
Specialist
1 Brucellosis publication
ZF
Zixu Fan
Specialist
1 Brucellosis publication
MJ
Min Jin
Specialist
1 Brucellosis publication
AA
Ashok Aspatwar
Specialist
1 Brucellosis publication
SA
Saeed O Alfadly
Specialist
1 Brucellosis publication
GE
Gamal O Elhassan
Specialist
1 Brucellosis publication
AG
Anusmita Ganguly
Specialist
1 Brucellosis publication
SP
Seppo Parkkila
Specialist
1 Brucellosis publication
MS
Mikhail Samsonov
Specialist
PI on 17 active trials
AL
Ali MA Ismail, lecturer
Specialist
PI on 5 active trials1 Brucellosis publication
CP
Claude Flamand, Ph.D.
Specialist
PI on 1 active trial
LM
Léa SAVEY, MD
Specialist
PI on 1 active trial1 Brucellosis publication
SP
Seda Saka, PT, PhD
Specialist
PI on 2 active trials
BM
Benjamin D Solomon, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 3 active trials
ÖD
Özge GÜNGÖR, PhD, DDS, Assoc. Prof. Dr.
Specialist
PI on 1 active trial
EM
Erkan Demirkaya, MD, MSc
Specialist
PI on 1 active trial
FP
François Chappuis, MD, PhD
Specialist
PI on 1 active trial
BH
Bassant H Abdel Hady
Specialist
1 Brucellosis publication
NF
Nada A Fahmy
Specialist
1 Brucellosis publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Brucellosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open BrucellosisForum →

No community posts yet. Be the first to share your experience with Brucellosis.

Start the conversation →

Latest news about Brucellosis

Disease timeline:

New recruiting trial: Outcomes of Inspiratory Muscle Training in FMF Adolescents

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Real World Study of Classic Infectious Disease

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Observing the Efficacy and Safety of Different Drugs Used in Real-world Familial Mediterranean Fever (FMF) Cases

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Characterization of a Functional Test for Mediterranean Family Fever Screening - 2

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy

A new clinical trial is recruiting patients for Brucellosis

New recruiting trial: Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

A new clinical trial is recruiting patients for Brucellosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Brucellosis

What is Brucellosis?

Brucellosis, also known as undulant fever, Malta fever, or Mediterranean fever, is a zoonotic infectious disease caused by bacteria of the genus Brucella. The most common species affecting humans include Brucella melitensis (from goats and sheep), Brucella abortus (from cattle), Brucella suis (from pigs), and Brucella canis (from dogs). Humans typically acquire the infection through consumption of unpasteurized dairy products, direct contact with infected animals or their secretions, or inhalation of contaminated aerosols. The disease is considered rare in developed countries but remains endem

Which specialists treat Brucellosis?

25 specialists and care centers treating Brucellosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.